TD Cowen initiated coverage of Mineralys Therapeutics with a Buy rating and no price target. The company's lorundrostat has broad, blockbuster potential in uncontrolled and resistant hypertension a $5B market, the analyst tells investors in a research note. TD believes lorundrostat will have a better label and favorable pricing relative to baxdrostat.
